Novel treatment strategies utilizing immune reactions against chronic myelogenous leukemia stem cells

Research output: Contribution to journalReview articlepeer-review

Abstract

Introduction of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myelogenous leukemia (CML), and treatment-free remission (TFR) is now a treatment goal. However, about half of the patients experience molecular relapse after cessation of TKIs, suggesting that leukemic stem cells (LSCs) are resistant to TKIs. Eradication of the remaining LSCs using immunotherapies including interferon-alpha, vaccinations, CAR-T cells, and other drugs would be a key strategy to achieve TFR.

Original languageEnglish
Article number5435
JournalCancers
Volume13
Issue number21
DOIs
Publication statusPublished - 2021 Nov 1

Keywords

  • Chronic myelogenous leukemia
  • Immunotherapy
  • Leukemic stem cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Novel treatment strategies utilizing immune reactions against chronic myelogenous leukemia stem cells'. Together they form a unique fingerprint.

Cite this